Legal Firm Faruqi & Faruqi Informs Investors of Geron Class Action Suit Deadlines
Faruqi & Faruqi Highlights Geron Corporation Class Action Lawsuit
Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, has taken steps to notify investors about a crucial development regarding Geron Corporation ("Geron" or "the Company," NASDAQ: GERN). The firm is currently investigating potential securities fraud claims against Geron and reminds all affected investors of the upcoming lead plaintiff deadline on May 12, 2025.
The firm encourages investors who have experienced losses exceeding $100,000 due to their investments in Geron between February 28, 2024, and February 25, 2025, to reach out directly to discuss their legal options. Faruqi & Faruqi partner, Josh Wilson, can be contacted at 877-247-4292 or 212-983-9330 (Ext. 1310).
The allegations against Geron include violations of federal securities laws, primarily due to misleading statements made by the Company and its executives regarding the commercial viability of Rytelo, a drug aimed at addressing a significant unmet medical need. According to the lawsuit, the executives expressed unwarranted confidence about Rytelo’s market potential while downplaying the accompanying risks such as the monitoring requirements and competitive market conditions.
On February 26, 2025, Geron reported its financial outcomes for the fourth quarter of fiscal 2024, revealing that Rytelo's sales had stagnated over previous months. This announcement cited various reasons for the decline, including competitive pressures, seasonal variations, and a lack of public awareness about the drug. Notably, following the adverse news, Geron’s stock price plummeted approximately 32.07%, dipping from $2.37 per share on February 25, to just $1.61 on February 26. This marked one of the steepest declines for the company in recent times, impacting the investment landscape significantly.
In circumstances such as these, a lead plaintiff plays a significant role in representing the interests of all affected shareholders in the class action. This individual must be the investor who holds the largest financial stake and meets the criteria of being typical and adequate as a representative of the class members. Interested individuals can submit a motion to serve as the lead plaintiff through counsel of their choice, or opt to remain as absent class members, knowing that their ability to recover compensation won't be hindered by their choice.
Faruqi & Faruqi are also reaching out to anyone possessing information concerning Geron's operations, including whistleblowers and former employees, to support their investigation. This represents an opportunity for potentially significant insights into the company’s practices leading to its legal troubles.
To gain further information about the ongoing Geron class action lawsuit, visit Faruqi & Faruqi’s dedicated website or utilize the aforementioned contact details to speak with partner Josh Wilson. It is crucial for impacted investors to act swiftly due to the impending deadlines and take stock of their legal rights in this case. Investors are encouraged to stay updated through the firm’s social media platforms, including LinkedIn, X, and Facebook.
In conclusion, the situation surrounding Geron Corporation underscores the broader implications of securities litigation and highlights the importance of investor rights in situations where there are allegations of misleading corporate statements. Through their proactive approach, Faruqi & Faruqi strives not only to secure justice for affected investors but also to bring to light important issues of corporate transparency and accountability.
Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, has taken steps to notify investors about a crucial development regarding Geron Corporation ("Geron" or "the Company," NASDAQ: GERN). The firm is currently investigating potential securities fraud claims against Geron and reminds all affected investors of the upcoming lead plaintiff deadline on May 12, 2025.
The firm encourages investors who have experienced losses exceeding $100,000 due to their investments in Geron between February 28, 2024, and February 25, 2025, to reach out directly to discuss their legal options. Faruqi & Faruqi partner, Josh Wilson, can be contacted at 877-247-4292 or 212-983-9330 (Ext. 1310).
The allegations against Geron include violations of federal securities laws, primarily due to misleading statements made by the Company and its executives regarding the commercial viability of Rytelo, a drug aimed at addressing a significant unmet medical need. According to the lawsuit, the executives expressed unwarranted confidence about Rytelo’s market potential while downplaying the accompanying risks such as the monitoring requirements and competitive market conditions.
On February 26, 2025, Geron reported its financial outcomes for the fourth quarter of fiscal 2024, revealing that Rytelo's sales had stagnated over previous months. This announcement cited various reasons for the decline, including competitive pressures, seasonal variations, and a lack of public awareness about the drug. Notably, following the adverse news, Geron’s stock price plummeted approximately 32.07%, dipping from $2.37 per share on February 25, to just $1.61 on February 26. This marked one of the steepest declines for the company in recent times, impacting the investment landscape significantly.
In circumstances such as these, a lead plaintiff plays a significant role in representing the interests of all affected shareholders in the class action. This individual must be the investor who holds the largest financial stake and meets the criteria of being typical and adequate as a representative of the class members. Interested individuals can submit a motion to serve as the lead plaintiff through counsel of their choice, or opt to remain as absent class members, knowing that their ability to recover compensation won't be hindered by their choice.
Faruqi & Faruqi are also reaching out to anyone possessing information concerning Geron's operations, including whistleblowers and former employees, to support their investigation. This represents an opportunity for potentially significant insights into the company’s practices leading to its legal troubles.
To gain further information about the ongoing Geron class action lawsuit, visit Faruqi & Faruqi’s dedicated website or utilize the aforementioned contact details to speak with partner Josh Wilson. It is crucial for impacted investors to act swiftly due to the impending deadlines and take stock of their legal rights in this case. Investors are encouraged to stay updated through the firm’s social media platforms, including LinkedIn, X, and Facebook.
In conclusion, the situation surrounding Geron Corporation underscores the broader implications of securities litigation and highlights the importance of investor rights in situations where there are allegations of misleading corporate statements. Through their proactive approach, Faruqi & Faruqi strives not only to secure justice for affected investors but also to bring to light important issues of corporate transparency and accountability.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.